Investors & Media

Press releases

Regeneron to Report Third Quarter 2026 Financial and Operating Results and Host Conference Call and Webcast on October 30, 2026

Regeneron Announces Investor Conference Presentations

Pasatru™ (garetosmab-grts) First and Only FDA-approved Treatment Demonstrating Reduction in New Heterotopic Ossification (HO) Lesions and Clinician-Assessed Flare-ups in a Placebo-controlled Trial in Adults with Fibrodysplasia Ossificans Progressiva (FOP)

Visit our newsroom

Upcoming & recent events

Regeneron Pharmaceuticals Q3 2026 Earnings Conference Call

Listen to webcast

View event details

View investor events

Quarterly materials

Show all

Q2 2026

Market Cap:

Sep 25, 2026 10:24 AM EDT

Minimum 15 minutes delayed. Source: LSEG

Interactive analyst center

Interactive and downloadable financial data for investors and analysts.

View analyst center

Corporate responsibility

We're dedicated to responsible business practices, integrating the highest standards of integrity into every facet of our operations.

Our TCFD (Task Force on Climate-related Financial Disclosures) Report, previously published as a standalone report, is now included in the appendix of our annual Responsibility Report.

Learn about our approach to corporate responsibility

Contact us

Investors

914.847.7741

invest@regeneron.com

Media

media@regeneron.com

Sign up for email alerts

Regeneron corporate and R&D headquarters